Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
作者信息
Izutsu Koji, Yamamoto Kazuhito, Kato Koji, Ishikawa Takayuki, Fukuhara Noriko, Terui Yasuhito, Choi Ilseung, Okubo Sumiko, Ogawa Natsumi, Sakai Mizu, Nishimura Yasuko, Chyla Brenda, Sun Yan, Maruyama Dai
机构信息
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan.
出版信息
Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3. Epub 2023 Aug 15.
Abstract
摘要
相似文献
1
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3. Epub 2023 Aug 15.
2
Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases.
J Clin Exp Hematop. 2024;64(2):152-155. doi: 10.3960/jslrt.24014.
3
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23.
4
[Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):247-250. doi: 10.3760/cma.j.issn.0253-2727.2023.03.012.
5
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Clin Pharmacol Ther. 2021 Feb;109(2):424-432. doi: 10.1002/cpt.2005. Epub 2020 Sep 6.
6
Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia.
N Engl J Med. 2023 Mar 9;388(10):952-954. doi: 10.1056/NEJMc2216135.
7
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24.
8
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
9
Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia.
Ann Hematol. 2023 Mar;102(3):681-682. doi: 10.1007/s00277-022-05067-4. Epub 2022 Dec 21.
10
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
本文引用的文献
1
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014.
2
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
Leukemia. 2021 Nov;35(11):3059-3072. doi: 10.1038/s41375-021-01241-1. Epub 2021 Jun 24.
3
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23.
4
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
BMC Cancer. 2020 Jun 30;20(1):612. doi: 10.1186/s12885-020-07077-9.
Zotero 插件